New drug applications approved by US FDA as of 16 - 31 December 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Routine prescription of a hypnotic medication does not appear to substantially reduce suicidal ideation in depressed outpatients with insomnia, but coprescription of such drug during antidepressant initiation may help suicidal outpatients, particularly those with severe insomnia, suggest the results of a study.
Fibromyalgia patients with comorbid insomnia more often receive prescription medications for fibromyalgia and use ambulatory care services relative to their counterparts without the sleep disorder, according to a study, suggesting that comorbidity with insomnia substantially increases its burden.
Use of opioid pain medication among adults with comorbid symptoms of insomnia and chronic pain appears to prolong time spent being awake in bed, reports a study, adding that such effect cannot be attributed to changes in pain, use of sleep medication or total sleep time.
Guided online Cognitive Behavioral Therapy for Insomnia (CBT-I) may be used in the management of both insomnia and depressive symptoms, with effect sizes being large and comparable to that of depression therapy, according to a study.
In this issue of MIMS PsychiatrySupplement, we bring you clinical updates related to managing depression and optimizing functional recovery in patients with depression, as well as a symposium highlight of the Lundbeck Malaysia Neuroscience Symposium.